메뉴 건너뛰기
Journal of Clinical Psychiatry
Volumn 66, Issue 8, 2005, Pages 1073-1074
Consensus development conference on antipsychotic drugs and obesity and diabetes: Response to consensus statement [2]
Author keywords

[No Author keywords available]
Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;
EID: 23944456070     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v66n0818c     Document Type: Letter
Times cited : (14)
References (10)
  • 1
    • 16644383497 scopus 로고    scopus 로고
    • Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement
    • Citrome L, Volavka J. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: response to consensus statement [letter]. Diabetes Care 2004;27:2087-2088
    • (2004) Diabetes Care , vol.27 , pp. 2087-2088
    • Chrome, L.1    Volavka, J.2
  • 2
    • 0842348094 scopus 로고    scopus 로고
    • Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
    • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601
    • (2004) Diabetes Care , vol.27 , pp. 596-601
  • 3
    • 1842844950 scopus 로고    scopus 로고
    • Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
    • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004;65:267-272
    • (2004) J Clin Psychiatry , vol.65 , pp. 267-272
  • 4
    • 0035988520 scopus 로고    scopus 로고
    • The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia
    • Marder SR, Essock SM, Miller AL, et al. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia. Schizophr Bull 2002;28:5-16
    • (2002) Schizophr Bull , vol.28 , pp. 5-16
    • Marder, S.R.1    Essock, S.M.2    Miller, A.L.3
  • 5
    • 0344844502 scopus 로고    scopus 로고
    • Relationship of atypical antipsychotics with development of diabetes mellitus
    • Citrome L, Jaffe A. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003;37:1849-1857
    • (2003) Ann Pharmacother , vol.37 , pp. 1849-1857
    • Citrome, L.1    Jaffe, A.2
  • 6
    • 3042741059 scopus 로고    scopus 로고
    • The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents
    • Citrome LL. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Barc) 2004;40:445-464
    • (2004) Drugs Today (Barc) , vol.40 , pp. 445-464
    • Citrome, L.L.1
  • 7
    • 0345443316 scopus 로고    scopus 로고
    • FDA to require diabetes warning on antipsychotics
    • Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatr News 2003;38(20):1
    • (2003) Psychiatr News , vol.38 , Issue.20 , pp. 1
    • Rosack, J.1
  • 8
    • 4444242571 scopus 로고    scopus 로고
    • Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications
    • Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-1711
    • (2004) Am J Psychiatry , vol.161 , pp. 1709-1711
    • Leslie, D.L.1    Rosenheck, R.A.2
  • 9
    • 0036268294 scopus 로고    scopus 로고
    • Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    • Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
    • (2002) Am J Psychiatry , vol.159 , pp. 1018-1028
    • Bilder, R.M.1    Goldman, R.S.2    Volavka, J.3
  • 10
    • 0037309666 scopus 로고    scopus 로고
    • Efficacy should drive atypical antipsychotic treatment
    • Citrome L. Efficacy should drive atypical antipsychotic treatment [letter]. BMJ 2003;326:283-284
    • (2003) BMJ , vol.326 , pp. 283-284
    • Citrome, L.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.